Glenmark gets USFDA approval for Clindamycin Phosphate Foam 1%

Glenmark


Chennai, Sep 21 : Pharma major Glenmark Pharmaceuticals Ltd on Tuesday said it has received final approval by the United States Food & Drug Administration (USFDA) for Clindamycin Phosphate Foam, 1 per cent, the generic version of Evoclin Foam, 1 per cent, of Mylan Pharmaceuticals Inc. According to IQVIA sales data for the 12 month period ending July 2021, the Evoclin Foam, 1 per cent, market achieved annual sales of approximately $12.0 million. Glenmark's current portfolio consists of 173 products authorized for distribution in the US marketplace and 47 ANDA's (Abbreviated New Drug Application) pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio, the company said. /IANS




Related

Glenmark gets USFDA approval for Clindamycin Phosphate Foam 1%
Chennai, Sep 21 : Pharma major Glenmark Pharmaceuticals Ltd on Tuesday said it has received final approval by the United States Food & Drug Administr

Antibodies from original Covid strain may not help fight variants
New York, Sep 21 : People infected with the original strain of the coronavirus that caused Covid-19 early in the pandemic produced a consistent antibo

Chicago Public Schools report 481 Covid cases in 3 weeks
Chicago, Sep 21 : Chicago Public Schools (CPS), the third largest school district in the US, has reported 481 Covid-19 cases with more than 9,600 clos